SCND 10-Q Quarterly Report Dec. 31, 2021

SCIENTIFIC INDUSTRIES INC

10-Ks and 10-Qs

10-Q	Quarter ended Sept. 30, 2025
10-Q	Quarter ended June 30, 2025
10-Q	Quarter ended March 31, 2025
10-K	Fiscal year ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-Q	Quarter ended Sept. 30, 2022
10-K	Fiscal year ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-Q	Quarter ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-K	Fiscal year ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-Q	Quarter ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-K	Fiscal year ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-Q	Quarter ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-K	Fiscal year ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-Q	Quarter ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-K	Fiscal year ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-Q	Quarter ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-K	Fiscal year ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-Q	Quarter ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-K	Fiscal year ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-Q	Quarter ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-K	Fiscal year ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-Q	Quarter ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-K	Fiscal year ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-Q	Quarter ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-K	Fiscal year ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-Q	Quarter ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-K	Fiscal year ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-Q	Quarter ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-K	Fiscal year ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-Q	Quarter ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-K	Fiscal year ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-Q	Quarter ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on April 15, 2024
DEF 14A	Filed on April 12, 2024
DEF 14A	Filed on Dec. 20, 2022
DEF 14A	Filed on Dec. 15, 2022
DEF 14A	Filed on Jan. 24, 2022
DEF 14A	Filed on June 30, 2021
DEF 14A	Filed on Jan. 22, 2021
DEF 14A	Filed on Dec. 26, 2019
DEF 14A	Filed on Dec. 19, 2018
DEF 14A	Filed on Dec. 14, 2017
DEF 14A	Filed on Dec. 7, 2016
DEF 14A	Filed on Dec. 4, 2014
DEF 14A	Filed on Nov. 1, 2013
DEF 14A	Filed on Oct. 26, 2012
DEF 14A	Filed on Dec. 8, 2011
DEF 14A	Filed on Dec. 7, 2010

scnd_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to________

Commission file number 0-6658

SCIENTIFIC INDUSTRIES, INC.

(Exact Name of Registrant as specified in Its Charter)

Delaware		04-2217279
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

80 Orville Drive , Suite 102 , Bohemia , New York		11716
(Address of principal executive offices)		(Zip Code)

( 631 ) 567-4700

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging Growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock, par value $.05 per share (“Common Stock”) as of February 4, 2022 is 6,458,143 shares.

SCIENTIFIC INDUSTRIES, INC.

Table of Contents

PART I - Financial Information

Item 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)	3

	Condensed Consolidated Balance Sheets	3

	Condensed Consolidated Statements of Operations and Comprehensive Loss	4

	Condensed Consolidated Statements of Changes in Shareholders’ Equity	5

	Condensed Consolidated Statements of Cash Flows	7

	Notes to Unaudited Condensed Consolidated Financial Statements	8

Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19

Item 4.	CONTROLS AND PROCEDURES	21

PART II - Other Information

Item 6.	EXHIBITS AND REPORTS ON FORM 8-K	22

SIGNATURE		23

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31, 2021			June 30, 2021
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,297,000		$	9,675,200
Investment securities		6,873,500			3,744,600
Trade accounts receivable, less allowance for doubtful accounts of $ 15,600 at December 31, 2021 and June 30, 2021		1,344,800			1,294,700
Inventories		3,615,000			2,977,100
Income tax receivable		66,000			333,300
Prepaid expenses and other current assets		580,600			350,900
Assets of discontinued operations		10,500			55,300
Total current assets		16,787,400			18,431,100

Property and equipment, net		522,600			412,600
Goodwill		4,395,400			4,395,400
Other intangible assets, net		2,350,400			2,557,800
Deferred taxes		3,223,200			2,489,900
Operating lease right-of-use assets		1,511,000			665,300
Other assets		62,500			54,300

Total assets	$	28,852,500		$	29,006,400

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	914,800		$	453,500
Accrued expenses		601,600			633,500
Contingent consideration		100,000			136,600
Bank overdraft		158,300			321,700
Lease liabilities, current portion		175,700			270,500
Paycheck Protection Program loan		-			433,800
Liabilities of discontinued operations		13,200			37,200
Total current liabilities		1,963,600			2,286,800

Contingent consideration payable, less current portion		-			23,400
Lease liabilities, less current portion		1,399,400			460,500
Other long-term liabilities		-			10,900

Total liabilities		3,363,000			2,781,600

Shareholders’ equity:
Common stock, $ .05 par value; 15,000,000 shares authorized; 6,477,945 shares issued; 6,458,143 shares outstanding at December 31, 2021 and June 30, 2021		324,000			324,000
Additional paid-in capital		27,879,900			26,613,500
Accumulated comprehensive gain (loss)		94,400			( 9,200	)
Accumulated deficit		( 2,756,400	)		( 651,100	)
		25,541,900			26,277,200
Less common stock held in treasury at cost, 19,802 shares		52,400			52,400
Total shareholders’ equity		25,489,500			26,224,800

Total liabilities and shareholders’ equity	$	28,852,500		$	29,006,400

See notes to unaudited condensed consolidated financial statements.

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)

	For the Three Month Period Ended December 31,			For the Three Month Period Ended December 31,			For the Six Month Period Ended December 31,			For the Six Month Period Ended December 31,
	2021			2020			2021			2020

Revenues	$	2,904,200		$	2,717,400		$	5,758,600		$	4,736,500

Cost of revenues		1,495,400			1,311,300			2,836,300			2,273,700

Gross profit		1,408,800			1,406,100			2,922,300			2,462,800

Operating expenses:
General and administrative		1,366,200			536,900			2,831,900			1,056,100
Selling		1,007,100			778,900			1,942,800			1,272,800
Research and development		880,300			329,700			1,516,800			574,000

Total operating expenses		3,253,600			1,645,500			6,291,500			2,902,900

Loss from operations		( 1,844,800	)		( 239,400	)		( 3,369,200	)		( 440,100	)

Other income:
Other income, net		496,800			18,200			466,200			16,200
Interest income		26,700			35,300			49,400			48,900
Total other income, net		523,500			53,500			515,600			65,100

Loss from continuing operations before income tax benefit		( 1,321,300	)		( 185,900	)		( 2,853,600	)		( 375,000	)

Income tax benefit, deferred		( 414,700	)		( 47,600	)		( 737,300	)		( 94,100	)

Loss from continuing operations		( 906,600	)		( 138,300	)		( 2,116,300	)		( 280,900	)

Discontinued operations (Note 9):

Gain (loss) from discontinued operations, net of tax		10,100			( 474,200	)		11,000			( 594,900	)

Net loss		( 896,500	)		( 612,500	)		( 2,105,300	)		( 875,800	)

Comprehensive gain (loss):
Unrealized holding loss on investment securities, net of tax		( 2,600	)		-			(400	)		-
Foreign currency translation adjustment		69,900			-			104,000			-
Comprehensive gain		67,300			-			103,600			-

Total comprehensive loss	$	( 829,200	)	$	( 612,500	)	$	( 2,001,700	)	$	( 875,800	)

Basic loss per common share

Continuing operations	$	( .14	)	$	( .05	)	$	( .33	)	$	( .10	)
Discontinued operations	$	.00		$	( .17	)	$	.00		$	( .21	)
Consolidated operations	$	( .14	)	$	( .22	)	$	( .33	)	$	( .31	)

See notes to unaudited condensed consolidated financial statements.

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (UNAUDITED)

							Accumulated
	Common Stock				Additional Paid-in		other Comprehensive Income			Retained Earnings (Accumulated			Treasury Stock				Total Shareholders’
	Shares		Amount		Capital		(Loss)			Deficit)			Shares		Amount		Equity

Balances, July 1, 2021		6,477,945	$	324,000	$	26,613,500	$	( 9,200	)	$	( 651,100	)		19,802	$	52,400	$	26,224,800

Net loss		-		-		-		-			( 1,208,800	)		-		-		( 1,208,800	)

Foreign currency translation adjustment		-		-		-		34,100			-			-		-		34,100

Unrealized holding gain on investment securities, net of tax		-		-		-		2,200			-			-		-		2,200

Stock-based compensation		-		-		675,400		-			-			-		-		675,400

Balances, September 30, 2021		6,477,945		324,000		27,288,900		27,100			( 1,859,900	)		19,802		52,400		25,727,700

Net loss		-		-		-		-			( 896,500	)		-		-		( 896,500	)

Foreign currency translation adjustment		-		-		-		69,900			-			-		-		69,900

Unrealized holding loss on investment securities, net of tax		-		-		-		( 2,600	)		-			-		-		( 2,600	)

Stock-based compensation		-		-		591,000		-			-			-		-		591,000

Balances, December 31, 2021		6,477,945	$	324,000	$	27,879,900	$	94,400		$	( 2,756,400	)		19,802	$	52,400	$	25,489,500

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (UNAUDITED)

					Additional									Total
	Common Stock				Paid-in		Retained			Treasury Stock				Shareholders’
	Shares		Amount		Capital		Earnings			Shares		Amount		Equity

Balance, July 1, 2020		2,881,065	$	144,100	$	8,608,300	$	3,021,400			19,802	$	52,400	$	11,721,400

Net loss		-		-		-		( 263,300	)		-		-		( 263,300	)

Stock-based compensation		-		-		61,300		-			-		-		61,300

Balance, September 30, 2020		2,881,065		144,100		8,669,600		2,758,100			19,802		52,400		11,519,400

Net loss		-		-		-		( 612,500	)		-		-		( 612,500	)

Stock-based compensation		-		-		76,100		-			-		-		76,100

Balance, December 31, 2020		2,881,065	$	144,100	$	8,745,700	$	2,145,600			19,802	$	52,400	$	10,983,000

See notes to unaudited condensed consolidated financial statements.

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the Six Month Period Ended December 31,			For the Six Month Period Ended December 31,
	2021			2020
Operating activities:
Net loss	$	( 2,105,300	)	$	( 875,800	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of investments		( 4,000	)		( 33,300	)
Unrealized holding loss on investments		32,600			25,700
Extinguishment of debt		( 433,800	)		-
Depreciation and amortization		327,300			83,000
Deferred income taxes		( 733,300	)		( 274,000	)
Loss on disposal of subsidiary		-			405,400
Stock-based compensation		1,266,400			137,400
Change in fair value of contingent consideration		( 60,000	)		-
Changes in operating assets and liabilities:
Trade accounts receivable		( 50,100	)		( 490,500	)
Inventories		( 637,900	)		( 53,500	)
Carrying value of right of use assets		( 1,600	)		9,800
Income tax receivable		267,300			1,200
Prepaid and other current assets		( 229,700	)		( 205,600	)
Accounts payable		461,300			266,900
Contract liabilities		-			( 20,000	)
Bank overdraft		( 163,400	)		181,900
Other assets		( 8,200	)		-
Discontinued operations		20,800			-
Other long-term liabilities		( 10,900	)		-
Accrued expenses and taxes		( 31,900	)		( 376,400	)
Total adjustments		10,900			( 342,000	)

Net cash used in operating activities		( 2,094,400	)		( 1,217,800	)

Investing activities:

Redemption of investment securities		844,300			544,800
Purchase of investment securities		( 4,001,200	)		( 5,990,200	)
Proceeds from sale of discontinued operations		-			342,400
Capital expenditures		( 163,400	)		( 82,900	)
Purchase of other intangible assets		( 66,500	)		( 31,300	)
Net cash used in investing activities		( 3,386,800	)		( 5,217,200	)

Financing activities:

Payments of contingent consideration		-			( 13,400	)

Net cash used in financing activities		-			( 13,400	)

Effect of changes in foreign currency exchange rates		103,000			-

Net decrease in cash and cash equivalents		( 5,378,200	)		( 6,448,400	)
Cash and cash equivalents, beginning of year		9,675,200			7,559,700
Cash and cash equivalents, end of period	$	4,297,000		$	1,111,300

SUPPLEMENTAL DISCLOSURES:
Cash paid during the period for:
Income taxes	$	-		$	2,500
Noncash financing activities:
Record right-of-use assets	$	941,300			-
Record lease liabilities	$	941,300			-

See notes to unaudited condensed consolidated financial statements.

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

General:

The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q. Accordingly, certain information and footnotes required by accounting principles generally accepted in the United States for complete financial statements are not included herein. The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature. These interim statements should be read in conjunction with the Company’s financial statements and notes thereto, included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2021. The results for the three and six months ended December 31, 2021 are not necessarily an indication of the results for the full fiscal year ending June 30, 2022.

1. Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary (discontinued operation as of November 30, 2020), Scientific Bioprocessing Holdings, Inc. (“SBHI”), a Delaware corporation, and SBHI’s wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation, and aquila biolabs GmbH (“Aquila”), a German corporation, which was acquired on April 29, 2021, (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated in consolidation.

COVID-19 Pandemic

The challenges posed by the COVID-19 pandemic on the global economy began to take effect and adversely affected the Company’s operations at the end of the third quarter of the fiscal year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the adverse effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action pertaining to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. SBI’s facility was shut down temporarily due to state mandates, however, the impact on operations was minimal, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program (“PPP”). The Company received $ 563,800 and $ 433,800 in PPP loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $ 32,700 which was repaid by the Company and the second loan was forgiven in full in December 2021. The Company elected to account for its PPP Loans in accordance with Accounting Standards Codification (“ASC”), 470 Debt, with interest, if any, accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. Initially, the Company recognized the entire loan amounts as liabilities on its balance sheets, and remain as liabilities until either the Company is legally released from its obligations or pays the lender. Once the loan is forgiven, the amount forgiven is recorded in the Company’s statement of operations as “Other Income.”

Adopted Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Simplifying the Accounting for Income Taxes”, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020. The adoption of this standard as of July 1, 2021 did not have a material impact on the Company’s financial statements.

Table of Contents

2. Revenue

The Company generates revenues from the following sources: (1) Benchtop Laboratory Equipment, and (2) Bioprocessing Systems.

The following table summarizes the Company’s disaggregation of revenues for the three and six months ended December 31, 2021 and 2020.

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Three Months Ended December 31, 2021:

Revenues	$	2,501,300	$	402,900	$	2,904,200

Foreign Sales		959,300		430,000		1,389,300

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Three Months Ended December 31, 2020:

Revenues	$	2,507,400	$	210,000	$	2,717,400

Foreign Sales		1,150,700		206,100		1,356,800

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Six Months Ended December 31, 2021:

Revenues	$	5,031,100	$	727,500	$	5,758,600

Foreign Sales		2,031,100		521,500		2,552,600

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Six Months Ended December 31, 2020:

Revenues	$	4,437,600	$	298,900	$	4,736,500

Foreign Sales		1,782,600		292,400		2,075,000

Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment sold to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment ranges from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90 days, depending on the customer. Once the item is shipped under the terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. The standard warranty is typically one or two years, covering parts and labor, and is deemed immaterial. Revenue is recognized at the point in time when the risks and rewards of ownership have transferred to the customer, which is generally upon shipment.

Bioprocessing Systems revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement included two United States patents, which expired in August 2021. The Company is obligated to pay 50% of all royalties earned to the entity that licensed the intellectual property to the Company.

Table of Contents

3. Segment Information and Concentrations

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”); and the design, manufacture, and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Three Months Ended December 31, 2021:

Revenues	$	2,501,300	$	402,900		$	-		$	2,904,200

Foreign Sales		959,300		430,000			-			1,389,300

Income (Loss) From Operations		290,100		(1,890,700	)		( 244,200	)		( 1,844,800	)

Assets		9,715,400		10,064,500			9,072,600			28,852,500

Long-Lived Asset Expenditures		32,800		148,200			-			181,000

Depreciation and Amortization		23,800		138,400			-			162,200

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Three Months Ended December 31, 2020:

Revenues	$	2,507,400	$	210,000		$	-		$	2,717,400

Foreign Sales		1,150,700		206,100			-			1,356,800

Income (Loss) From Operations		568,500		(741,800	)		( 66,100	)		( 239,400	)

Assets		6,140,400		966,400			6,962,800			14,069,600

Long-Lived Asset Expenditures		13,700		13,800			-			27,500

Depreciation and Amortization		26,400		15,800			200			42,400

Approximately 44 % and 52 % of net sales of Benchtop Laboratory Equipment for the three months ended December 31, 2021 and 2020, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 29 % and 23 % of total Benchtop Laboratory Equipment sales were derived from the Torbal Scales Division for the three months ended December 31, 2021 and 2020, respectively. For the three months ended December 31, 2021 and 2020, respectively, three customers accounted for approximately 20 % for both periods of net sales of the Benchtop Laboratory Equipment Operations ( 17 % and 18 % of the Company’s total revenues), respectively.

Sales of products from Aquila of the Bioprocessing Systems Operations, amounted to $332,400 for the three months ended December 31, 2021 and none in the corresponding prior year period.

Table of Contents

3. Segment Information and Concentrations (Continued)

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Six Months Ended December 31, 2021:

Revenues	$	5,031,100	$	727,500		$	-		$	5,758,600

Foreign Sales		2,031,100		521,500			-			2,552,600

Income (Loss) From Operations		851,700		(3,712,700	)		( 508,200	)		( 3,369,200	)

Assets		9,715,400		10,064,500			9,072,600			28,852,500

Long-Lived Asset Expenditures		66,600		163,300			-			229,900

Depreciation and Amortization		46,600		280,700			-			327,300

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Six Months Ended December 31, 2020:

Revenues	$	4,437,600	$	298,900		$	-		$	4,736,500

Foreign Sales		1,782,600		292,400			-			2,075,000

Income (Loss) From Operations		952,300		(1,274,100	)		( 118,300	)		( 440,100	)

Assets		6,140,400		966,400			6,962,800			14,069,600

Long-Lived Asset Expenditures		35,500		78,700			-			114,200

Depreciation and Amortization		52,700		29,800			500			83,000

Approximately 48 % and 50 % of total benchtop laboratory equipment sales ( 42 % and 47 % of total revenues) for the six months ended December 31, 2021 and 2020, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 25 % for both periods of total benchtop laboratory equipment sales ( 22 % and 23 % of total revenues) were derived from the Torbal Scales Division for the six months ended December 31, 2021 and 2020, respectively. For the six months ended December 31, 2021 and 2020, three customers accounted for approximately 21 % for both periods of net sales of the Benchtop Laboratory Equipment Operations ( 18 % and 20 % of the Company’s total revenues), respectively.

Table of Contents

4. Fair Value of Financial Instruments

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.

The fair value of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table.

The following tables set forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis at December 31, 2021 and June 30, 2021 according to the valuation techniques the Company used to determine their fair values:

	Fair Value at		Fair Value Measurements Using Inputs Considered as
	December 31, 2021		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	4,297,000	$	4,297,000	$	-	$	-
Investment securities		6,873,500		6,873,500		-		-

Total	$	11,170,500	$	11,170,500	$	-	$	-

Liabilities:
Contingent consideration	$	100,000	$	-	$	-	$	100,000

	Fair Value at		Fair Value Measurements Using Inputs Considered as
	June 30, 2021		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	9,675,200	$	9,675,200	$	-	$	-
Investment securities		3,744,600		2,920,600		824,000		-

Total	$	13,419,800	$	12,595,800	$	824,000	$	-

Liabilities:
Contingent consideration	$	160,000	$	-	$	-	$	160,000

Investments in marketable securities by security type at December 31, 2021 and June 30, 2021 consisted of the following:

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At December 31, 2021:
Equity securities	$	119,500	$	178,900	$	59,400
Mutual funds		6,705,700		6,694,600		( 11,100	)

	$	6,825,200	$	6,873,500	$	48,300

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2021:
Equity securities	$	102,200	$	154,100	$	51,900
Mutual funds		2,752,400		2,766,500		14,100
Debt securities		832,700		824,000		( 8,700	)

	$	3,687,300	$	3,744,600	$	57,300

Table of Contents

5 . Inventories

	December 31, 2021		June 30, 2021
Raw materials	$	2,372,500	$	2,170,400
Work-in-process		94,300		39,600
Finished goods		1,148,200		767,100
	$	3,615,000	$	2,977,100

6 . Goodwill and Finite Lived Intangible Assets

Goodwill amounted to $ 4,395,400 at December 31, 2021 and June 30, 2021, all of which is expected to be deductible for tax purposes.

The components of finite lived intangible assets are as follows:

	Useful Lives	Cost		Accumulated Amortization		Net
At December 31, 2021:
Technology, trademarks	5 - 10 yrs.	$	817,000	$	412,800	$	404,200
Trade names	3 - 6 yrs.		140,000		140,000		-
Websites	3 - 7 yrs.		210,000		210,000		-
Customer relationships	4 - 10 yrs.		372,200		122,800		249,400
Sublicense agreements	10 yrs.		294,000		294,000		-
Non-compete agreements	4 - 5 yrs.		1,060,500		406,400		654,100
In-process research and development	3 - 5 yrs.		918,600		209,200		709,400
Patents	5 - 7 yrs.		591,500		258,200		333,300

		$	4,403,800	$	2,053,400	$	2,350,400

	Useful Lives	Cost		Accumulated Amortization		Net
At June 30, 2021:
Technology, trademarks	5-10 yrs.	$	364,700	$	362,200	$	2,500
Trade names	3-6 yrs.		592,300		152,600		439,700
Websites	3-7 yrs.		210,000		210,000		-
Customer relationships	4-10 yrs.		372,200		102,400		269,800
Sublicense agreements	10 yrs.		294,000		283,000		11,000
Non-compete agreements	4-5 yrs.		1,060,500		308,600		751,900
In-process research and development	3-5 yrs.		852,100		134,800		717,300
Patents	5-7 yrs.		591,500		225,900		365,600

		$	4,337,300	$	1,779,500	$	2,557,800

Total amortization expense was $ 135,000 and $ 16,200 for the three months ended December 31, 2021 and 2020, respectively, and $ 273,900 and $ 32,000 for the six months ended December 31, 2021 and 2020, respectively. As of December 31, 2021, estimated future amortization expense related to intangible assets is $263,200 for the remainder of the fiscal year ending June 30, 2022, $ 520,300 for fiscal 2023, $ 508,800 for fiscal 2024, $ 474,100 for fiscal 2025, $ 272,400 for fiscal 2026 and $ 311,600 thereafter.

Table of Contents

7. Loss Per Common Share

The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income, if any, by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive; accordingly, no dilution is shown for loss periods. The following table sets forth the weighted average number of common shares outstanding for each period presented.

	For the Three Month Period Ended December 31, 2021			For the Three Month Period Ended December 31, 2020			For the Six Month Period Ended December 31, 2021			For the Six Month Period Ended December 31, 2020

Weighted average number of common shares outstanding		6,458,143			2,861,263			6,458,143			2,861,263
Effect of dilutive securities		-			-			-			-
Weighted average number of dilutive common shares outstanding		6,458,143			2,861,263			6,458,143			2,861,263

Basic loss per common share:

Continuing operations	$	( .14	)	$	( .05	)	$	( .33	)	$	( .10	)
Discontinued operations	$	.00		$	( .17	)	$	.00		$	( .21	)
Consolidated operations	$	( .14	)	$	( .22	)	$	( .33	)	$	( .31	)

Approximately 3,288,927 and 3,367,555 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and six months ended December 31, 2021. Approximately, 126,700 and 1,349,850 shares of the Company’s common stock issuable upon the exercise of outstanding options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and six months ended December 31, 2020.

Table of Contents

8. Leases

The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through October 2028, a facility in Pittsburgh, Pennsylvania for SBI’s Bioprocessing Systems Operations through May 2023, and a facility for sales and administration in Orangeburg, New York through October 2022. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities; and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below.

The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0 % as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.

The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.

The Company elected available practical expedients for existing or expired contracts of lessees whereby the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.

As of December 31, 2021, the weighted-average remaining lease term for operating lease liabilities was approximately 6.83 years and the weighted-average discount rate was 5.0 %. Total cash payments under these leases were approximately $ 89,800 and $ 158,100 , for the three and six months ended December 31, 2021 of which $ 81,800 and $ 144,400 was recorded as leases expense, respectively.

The Company’s approximate future minimum rental payments under all leases existing at December 31, 2021 through October 2028 are as follows:

Fiscal year ending June 30,	Amount
Remainder of 2022	$	164,200
2023		311,400
2024		247,600
2025		255,000
2026		262,700
Thereafter		609,600

Total future minimum payments	$	1,850,500
Less imputed interest		( 275,400	)

Total Present Value of Operating Lease Liabilities	$	1,575,100

Table of Contents

9. Discontinued Operations

Effective November 30, 2020, as part of its strategic shift to becoming a life sciences tool provider, the Company sold its operations relating to the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical petrochemical companies sold on direct basis (the “ Catalyst Research Instruments Operations”) through the sale by Altamira of substantially all of its assets, and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $ 440,000 which was fully paid in cash by January 2021, resulting in a $ 405,400 pre-tax loss. To preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which have been shipped, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was completed at the end of December 2020.

As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below.

Assets:	December 31, 2021		June 30, 2021
Cash	$	1,100	$	-
Accounts receivable		9,400		52,000
Inventories		-		3,300

Discontinued operations	$	10,500	$	55,300

Liabilities:	December 31, 2021		June 30, 2021
Accrued expenses and taxes	$	5,300	$	20,700
Contract liabilities		7,900		16,500

	$	13,200	$	37,200

Table of Contents

9. Discontinued Operations (continued)

	Three Months Ended					Six Months Ended
	December 31, 2021		December 31, 2020			December 31, 2021		December 31, 2020

Revenues	$	19,400	$	142,700		$	20,600	$	279,900
Cost of goods sold		3,400		195,500			3,400		379,700
Gross profit		16,000		( 52,800	)		17,200		( 99,800	)
Selling, general and administrative expenses		1,900		181,300			2,200		269,600
Gain (loss) from operations		14,100		( 234,100	)		15,000		( 369,400	)
Loss on disposal		-		( 405,400	)		-		( 405,400	)
Income (loss) from operations before income tax benefit		14,100		(639,500	)		15,000		( 774,800	)
Income tax expense, all deferred		4,000		165,300			4,000		179,900
Net income (loss) attributable to discontinued operations	$	10,100	$	(474,200	)	$	11,000	$	( 594,900	)

In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash provided by (used in) operating activities from discontinued operations for six months ended December 31, 2021 and December 30, 2020 was $ 1,100 and $( 335,000 ), respectively. There was no cash provided by or used in investing or financing activities for both periods.

10 . Acquisition of Aquila Biolabs GmbH

Effective April 29, 2021, pursuant to a Stock Purchase Agreement (“SPA”) the Company acquired all the outstanding capital stock of Aquila, a German start-up company engaged from its facility in Baesweiler, Germany in the design, production, and sale of bioprocessing systems and products which focus on the control and analysis of bioprocesses in bioreactors and incubation shakers for an aggregate purchase price of $ 7,880,100 in cash upon closing. Aquila’s principal customers are universities, pharmaceutical companies, and industrial companies. Aquila’s products are sold primarily on a direct basis and to a lesser extent, through distributors.

The acquisition was accounted for in accordance with ASC 805, Business Combinations (“ASC 805”) in which the Company is treated as the accounting acquirer. Accordingly, the assets acquired and liabilities assumed have been measured at estimated fair value.

For purposes of measuring the estimated fair value, where applicable, of the assets acquired and liabilities assumed, as reflected in the unaudited pro forma condensed consolidated financial information, the guidance in ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) has been applied, which establishes a framework for measuring fair value. In accordance with ASC 820, fair value is an exit price and is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Under ASC 805, acquisition-related transaction costs and acquisition-related restructuring charges are not included as components of consideration transferred but are accounted for as expenses in the period in which the costs are incurred.

Table of Contents

10 . Acquisition of Aquila Biolabs GmbH (continued)

Management of the Company allocated the purchase price based on its estimated valuation of the assets acquired and liabilities assumed as follows:

	Amount			Useful life
Fair value of assets acquired:
Current assets:
Cash and cash equivalents	$	201,100
Accounts receivable		159,200
Inventory		187,500
Prepaid expenses and other current assets		25,400
Property, plant and equipment		40,200
Deferred tax asset		800,300
Tradename		452,300		6 years
Non-compete agreements		784,500		4 years
In-process research and development		742,100		5 years
Customer relationships		252,200		9 years
Patents and other intangibles		286,200		7 years
Total assets acquired	$	3,931,000

Fair value of liabilities assumed:
Accounts payable	$	( 39,300	)
Accrued expenses		( 90,300	)
Other current liabilities		( 59,400	)
Total liabilities assumed	$	( 189,000	)

Total identifiable net assets	$	3,742,000
Fair value of consideration transferred		7,880,100
Goodwill	$	4,138,100

11. Paycheck Protection Program Loan

The Company received a second $ 433,800 PPP loan in March 2021, pursuant to the PPP loan administered by the U.S. Small Business Administration through its bank. The full amount of this loan was forgiven in December 2021, and is reflected as other income (extinguishment of debt) in the accompanying statements of operations and comprehensive loss.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking statements. Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company’s business that are beyond the Company’s control, which are discussed elsewhere in this report. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s financial statements and the related notes included elsewhere in this report.

Overview. The Company’s results reflect the results from the Benchtop Laboratory Equipment Operations and the Bioprocessing Systems Operations, which includes the results for Aquila following its acquisition on April 29, 2021. The Company realized a loss from continuing operations before income tax benefit of $1,321,300 and $2,853,600 for the three and six months ended December 31, 2021 compared to a loss from continuing operations before income tax benefit of $185,900 and $375,000 for the three and six months ended December 31, 2020, respectively, primarily due to increased operating expenses of its Bioprocessing Systems Operations, which included significant expenditures for product development, sales and marketing, and non-cash compensation expense related to stock options, partially offset by the profits generated by the Benchtop Laboratory Equipment Operations.

COVID-19 Pandemic . The Company has not experienced and does not expect to experience any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies, and pharmaceutical companies, which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. The Company also has not experienced and does not expect to experience any material impairment to its tangible and intangible assets, system of internal controls, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic, which are uncertain and cannot be predicted at this time. The Company has experienced supply chain disruptions which has had an impact on its operations causing delayed delivery of some products to its customers, and production inefficiencies. As of December 31, 2021, the Company had a total backlog of approximately $853,000 in benchtop laboratory equipment orders, compared to $860,000 as of December 31, 2020.

In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel has been and may be restricted in the future from traveling to conduct its operations including trade shows, site visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company. The operations of Aquila were negatively affected in their ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities were lost as a result.

Results of Operations.

The Three Months Ended December 31, 2021 Compared With The Three Months Ended December 31, 2020

Net revenues for the three months ended December 31, 2021 increased $186,800 (6.9%) to $2,904,200 from $2,717,400 for the three months ended December 31, 2020, reflecting an increase of $192,900 (49.0%) in net revenues due to product revenues derived from Aquila, partially offset by a decrease of $6,100 in sales of the Benchtop Laboratory Equipment due to decreased sales of its Genie brand products, partially offset by increased sales of its Torbal® brand products. The Benchtop Laboratory Equipment sales reflected $735,400 of Torbal brand product sales for the three months ended December 31, 2021, compared to $576,800 for the three months ended December 31, 2020 primarily due to increased sales of its automated VIVID pill counter.

The gross profit percentage on a combined basis was 48.5% for the three months ended December 31, 2021 compared to 51.7% for the three months ended December 31, 2020, due primarily to decreased margins for the Benchtop Laboratory Equipment Operations resulting from increased labor costs and materials.

General and administrative expenses for the three months ended December 31, 2021 increased by $829,300 (154.5%) to $1,366,200 from $536,900 for the three months ended December 31, 2020 due primarily to stock option compensation-related costs, newly incurred costs by Aquila of the Bioprocessing Systems Operations, and corporate expenses.

Selling expenses for the three months ended December 31, 2021 increased $228,200 (29.3%) to $1,007,100 from $778,900 for the three months ended December 31, 2020, and were incurred primarily by the by the Bioprocessing Systems operations for sales and marketing personnel, sales and marketing activities, and stock option compensation-related costs.

Table of Contents

Research and development expenses increased by $550,600 (167.0%) to $880,300 for the three months ended December 31, 2021 compared to $329,700 for the three months ended December 31, 2020, mainly due to product development costs incurred by the Bioprocessing Systems Operations’ Aquila operation which was acquired in the fourth quarter of fiscal 2021, and to a lesser extent to increased product development costs related to the Benchtop Laboratory Equipment Operations.

Total other income, net for the three months ended December 31, 2021 was $523,500 reflecting $433,800 of loan forgiveness for the Company’s second PPP Loan, compared to $53,500 for the three months ended December 31, 2020.

The Company reflected income tax benefit for continuing operations of $414,700 for the three months ended December 31, 2021 compared to income tax benefit of $47,600 for the three months ended December 31, 2020, primarily due to the increased loss.

As a result of the foregoing, the Company recorded a loss from continuing operations of $906,600 for the three months ended December 31, 2021 compared to a loss from continuing operations of $138,300 for the three months ended December 31, 2020.

The Company reflected a gain from discontinued operations of $10,100 for the three months ended December 31, 2021, compared to a loss of $474,200 for the three months ended December 31, 2020, due to miscellaneous income derived during the current year period.

The Six Months Ended December 31, 2021 Compared With The Six Months Ended December 31, 2020

Net revenues for the six months ended December 30, 2021 increased $1,022,100 (21.6%) to $5,758,600 from $4,736,500 for the six months ended December 31, 2020, reflecting an increase of $593,500 in sales of the Benchtop Laboratory Equipment due to increased sales of its Genie brand and Torbal brand products. The Benchtop Laboratory Equipment sales reflected $1,245,300 of Torbal brand product sales for the six months ended December 31, 2021, compared to $1,094,500 for the six months ended December 31, 2020 primarily due to increased sales of its automated VIVID pill counter. Revenues from the Bioprocessing Systems Operations increased $428,600 due primarily to sales by Aquila.

The gross profit percentage on a combined basis was 50.7% for the six months ended December 31, 2021 compared to 52.0% for the six months ended December 31, 2020 due primarily to decreased margins for the Benchtop Laboratory Equipment Operations resulting from increased costs for labor and materials.

General and administrative expenses for the six months ended December 31, 2021 increased by $1,775,800 (168.1%) to $2,831,900 from $1,056,100 for the six months ended December 31, 2020 due primarily to stock option compensation-related costs, newly incurred costs by Aquila of the Bioprocessing Systems Operations, and corporate expenses.

Selling expenses for the six months ended December 31, 2021 increased $670,000 (52.6%) to $1,942,800 from $1,272,800 for the six months ended December 31, 2020 which were incurred primarily by the Bioprocessing Systems Operations for sales and marketing personnel, sales and marketing activities, and stock option compensation-related costs.

Research and development expenses increased by $942,800 (164.3%) to $1,516,800 for the six months ended December 31, 2021 compared to $574,000 for the six months ended December 31, 2020, mainly due to product development costs incurred by the Bioprocessing Systems Operations’ Aquila operation which was acquired in the fourth quarter of fiscal 2021, and to a lesser extent to increased product development costs related to the Benchtop Laboratory Equipment Operations.

Total other income, net for the six months ended December 31, 2021 was $515,600 reflecting $433,800 loan forgiveness for the Company’s second PPP Loan, compared to $65,100 for the six months ended December 31, 2020.

The Company reflected income tax benefit for continuing operations of $737,300 for the six months ended December 31, 2021 compared to income tax benefit of $94,100 for the six months ended December 31, 2020, primarily due to the increased loss.

As a result of the foregoing, the Company recorded a loss from continuing operations of $2,116,300 for the six months ended December 31, 2021, compared to a loss from continuing operations of $280,900 for the six months ended December 31, 2020.

The Company reflected a gain from discontinued operations of $11,000 for the six months ended December 31, 2021, compared to a loss of $594,900 loss for the six months ended December 31 2020, due to miscellaneous income earned during the current year period.

Liquidity and Capital Resources. Cash and cash equivalents decreased by $5,378,200 to $4,297,000 as of December 31, 2021 from $9,675,200 as of June 30, 2021, due primarily the Company’s purchases of investment securities and the loss during the period.

Table of Contents

Net cash used in operating activities was $2,094,400 for the six months ended December 31, 2021 compared to $1,217,800 during the six months ended December 31, 2020, primarily as a result of the increased loss incurred for the current period. Net cash used in investing activities was $3,386,800 for the six months ended December 31, 2021 compared to $5,217,200 used during the six months ended December 31, 2020 principally due to a decrease of purchases and redemptions of investments, and to a lesser extent the Company’s purchase of new capital equipment. Net cash used in financing activities was zero for the six months ended December 31, 2021, compared to $13,400 used during the six months ended December 31, 2020, all due to contingent consideration.

The Company’s working capital decreased by $1,320,500 to $14,823,800 as of December 31, 2021 compared to $16,144,300, as of June 30, 2021 reflecting the loss generated during the period.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, based on an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), the Chief Executive and Chief Financial Officer of the Company has concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the Securities and Exchange Commission’s rules and forms. The Company also concluded that information required to be disclosed in such reports is accumulated and communicated to the Company’s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Table of Contents

PART II – OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

Exhibit Number		Description

31.		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Reports on Form 8-K:

Current Report filed on Form 8-K dated December 10, 2021 reporting under Item 8.01.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		SCIENTIFIC INDUSTRIES, INC. (Registrant)

Date: February 16, 2022		/s/ Helena R. Santos
		Helena R. Santos President, Chief Executive Officer, Chief Financial Officer and Treasurer

TABLE OF CONTENTS

Part I Financial Information Item 1. Financial Statements Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 4. Controls and Procedures Part II Other Information Item 6. Exhibits and Reports on Form 8-k

Exhibits

31. Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32. Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SCND 10-Q Quarter ended Dec. 31, 2021

Exhibits